Fresenius Medical Care AG & Co. KGaA
NYSE:FMSMedical - Care Facilities
-$0.18 today
- Market cap
- $11.26B
- Beta
- 0.81
- P/E (TTM)
- 11.9
- EPS (TTM)
- $3.43
- Dividend yield
- 3.65%
Volume 1.92M
Average 0.72M
FMS Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Fresenius Medical Care AG & Co. KGaANYSE: FMS
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables growth accelerates
Q2 FY2026 accounts receivables of €252.63M rose 37.7% year over year, ahead of the -124.5% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at +12.4% a year.
Context
- Accounts receivables amounted to 0.3% of revenue in FY2025, unchanged from a year earlier.
- Accounts receivables grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +37.7% holds above the trailing-twelve-month pace of -124.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
EUR · from the cash flow
- Latest · FY2025
- (66.34M) EUR
- Year-over-year change
- +9.7%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (66.34M) | +9.7% |
| FY2024 | 2024-12-31 | (73.48M) | +51.6% |
| FY2023 | 2023-12-31 | (151.84M) | -225.3% |
| FY2022 | 2022-12-31 | (46.68M) | +71.4% |
| FY2021 | 2021-12-31 | (163.2M) | — |
Accounts Receivables vs competitors
How FMS compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -124.5% is the lowest of 4, against a peer median of -76.0%.
- Accounts receivables amounts to 0.5% of revenue for FMS, versus a peer median of 0.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €93.4M EUR | -124.5% | +12.4% | 0.5% | |
| LTM Jun 2026 | $53.62M USD | +142.9% | +12.4% | 0.4% | |
| LTM Sep 2026 | $13.84M USD | -76.0% | +168.7% | 2.1% | |
| LTM Mar 2026 | $1.97M USD | -94.6% | — | 0.8% | |
| Peer median (excluding FMS) | — | -76.0% | +90.5% | 0.8% | |
Competitors are the stored peer set for FMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.22B | 894.33M | 732.46M | 740.87M | 939.75M |
| Depreciation & Amortization | 1.62B | 1.84B | 1.75B | 1.74B | 1.5B |
| Deferred Income Tax | 67.26M | (41.47M) | (122.15M) | (72.67M) | (26.14M) |
| Stock-Based Compensation | 0 | 0 | 32.52M | 0 | 0 |
| Change in Working Capital | (97.77M) | (128.07M) | 561.28M | 444.31M | 132.78M |
| Accounts Receivables | (163.2M) | (46.68M) | (151.84M) | (73.48M) | (66.34M) |
| Inventory | (48.53M) | (204.31M) | (13.14M) | 107.9M | (238.84M) |
| Accounts Payables | (363.96M) | (356.79M) | 108.48M | 155.59M | (14.18M) |
| Other Working Capital | 477.91M | 479.71M | 617.78M | 254.3M | 452.14M |
| Other Non-Cash Items | (322.7M) | (395.77M) | (327.27M) | (468.62M) | 28.38M |
| Operating Cash Flow | 2.49B | 2.17B | 2.63B | 2.39B | 2.58B |
| Capital Expenditures | (854.36M) | (723.99M) | (684.6M) | (699.36M) | (879.24M) |
| Acquisitions (Net) | (381.73M) | 1.03M | 137M | 606.68M | 223.34M |
| Purchases of Investments | (129.08M) | (105.64M) | (102.36M) | (81.5M) | (85.99M) |
| Sales of Investments | 144.52M | 57.67M | 89.6M | 75.13M | 80.2M |
| Other Investing Activities | 24.42M | 36.21M | 16.14M | 14.1M | 0 |
| Investing Cash Flow | (1.2B) | (734.73M) | (544.23M) | (84.94M) | (666.18M) |
| Debt Repayment | (358.9M) | (1.12B) | (1.19B) | (1.91B) | 767.1M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (562.19M) |
| Dividends Paid | (392.46M) | (395.56M) | (328.62M) | (349.16M) | (405.84M) |
| Other Financing Activities | (273.02M) | (103.8M) | (340.11M) | (314.99M) | (1.17B) |
| Financing Cash Flow | (1.02B) | (1.62B) | (1.86B) | (2.57B) | (1.38B) |
| Effect of Forex Changes | 131.23M | (23.16M) | (72.61M) | 26.2M | 24.97M |
| Net Change in Cash | 400.12M | (207.87M) | 153.44M | (241.9M) | 558.32M |
| Free Cash Flow | 1.64B | 1.44B | 1.94B | 1.69B | 1.7B |
Fresenius Medical Care AG & Co. KGaA
NYSE:FMS
Intrinsic Alpha fair value
Locked
Current Price
$20.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.